EDWARDS-LIFESCIENCES
21.6.2022 10:02:03 CEST | Business Wire | Press release
Edwards Lifesciences today published ‘Unifying Generations: Building the Pathway to Intergenerational Solidarity’ – a report, based on a survey of 12,850 Europeans across generations, that demonstrates the need to change perceptions of the value of people aged over-65 and their cohesion with younger generations.
“The European population is ageing. By 2040, 155 million people are expected to be over 651 . This demographic change is often referred to as a challenge, which gives a misleading and negative impression of the contributions of over-65s to the society, ” commented Jean-Luc Lemercier, Corporate Vice President, EMEA, Canada and Latin America, Edwards Lifesciences. “The survey results demonstrate that the senior population, and especially the pivotal 3rd generation, is an active, committed and engaged contributor to cohesion within families and the community. ”
To provide insights on the role of the senior population in society and the benefits of intergenerational interactions, Edwards Lifesciences joined forces with experts to conduct a survey examining the perceptions and experience of intergenerational solidarity of 12,850 citizens across 6 European countries (France, Germany, Ireland, Italy, Spain, and the UK). The results formed the basis of the newly available Unifying Generations report.
In contrast to existing perceptions, the survey results highlighted the significant social contributions of the 3rd generation. They contribute to their families and communities, through volunteering (19%) and providing care to others (24%).2 Seventy-one percent (71%) of over-65s also provide significant financial support to younger people.2 Younger generation respondents stated how important they felt the support the older generation provided was in their day-to-day lives, with 83% stating it was very important or somewhat important.2
“The Unifying Generations Survey gives an accurate picture of the current situation of intergenerational solidarity in several European countries. The results of this survey show a strong desire for more intergenerational interactions from both younger and older generations. The survey also presents the great value of listening, mentoring and coaching; contributing to community well-being through volunteering; sharing knowledge of new technology and digital skills; and many other ways of encouraging cooperation in a society for all ages. The survey data is a useful reference document that will encourage social organisations to promote intergenerational solidarity programs at local, national and international levels in European countries, ” commented Mr. Angel Yagüe Criado, Project Manager, The Spanish Confederation of Older People’s Association (CEOMA).
Results showed that the pandemic seems to have had a negative impact on intergenerational interaction, with 40% of respondents saying they spend less time with different generations since the pandemic.2 However, one of the most positive themes that emerged from the report was the willingness to improve intergenerational interactions. Respondents were 11 times more likely to think closer relations between different generations are a good thing (77%) vs. a bad thing (7%). 2 In fact, 92% of survey respondents confirmed they were open to having a friend from a different generation.
“The study suggests that extremely positive and varied intergenerational interactions are present in society and also valued by all age groups. It’s important that policies and strategies are developed that help maintain and strengthen these relations going forward, ” said Prof George W Leeson, Professorial Fellow, Oxford Institute of Population Ageing, University of Oxford.
A number of different benefits of improving intergenerational interactions were also highlighted. The most important benefits identified were companionship or friendship (20%) and mental and emotional wellbeing (19%). Additionally, 23% of younger respondents believe that mentoring or educational schemes provided by national or local government would help them to do more with older generations.2
The report recommends three actions that can be considered as a result of the survey findings. They are: a campaign to transform perceptions of the value of senior people and their interactions with younger generations, greater opportunities for mentoring and knowledge sharing from older to younger generations; and schemes that help senior people interact more digitally.
“Recognising and celebrating the knowledge, skills, and experiences of senior people is at the heart of the report and of promoting intergenerational solidarity ,” added Jean-Luc Lemercier. “As we build back after the pandemic, we should change perceptions of the value our senior populations – particularly the pivotal 3rd generation – provide to society and the importance of protecting their health and well-being .”
To learn more and download the full report please visit https://www.edwards.com/ch-en/aboutus/unifying-generations/ .
About Edwards Lifesciences
Edwards Lifesciences, is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape. For more information, visit Edwards.com and follow us on LinkedIn and Twitter .
Edwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.
About Unifying Generations
Unifying Generations is an initiative that springs from the company’s commitment to the patients it serves and illustrates the aspiration to create a community unified in its mission to improve the quality of life around the world.
###
1 Eurostat (2017) People in the EU – population projections, http://ec.europa.eu/eurostat/statistics-explained/index.php?-title=People_in_the_EU_-_population_projections
2 Censuswide. Unifying Generations. A survey of over 12,850 people in Europe. Survey carried out 04/04/2022 – 14/04/2022. Data on file. Survey funded by Edwards Lifesciences.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005242/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hisense Delivers 38% Sales Uplift in Western Europe Markets With NIQ’s AI-Powered Market Intelligence6.5.2026 05:00:00 CEST | Press release
NIQ insights drive international expansion and measurable growth for Hisense across key global markets NIQ (NYSE: NIQ), a global leader in consumer intelligence, today shared new learnings from its long-standing collaboration with Hisense, a leading global brand in home appliances and smart technologies. Using NIQ’s AI‑powered market intelligence, Hisense has accelerated international expansion, improved local market decision-making, and delivered measurable growth across more than 20 key markets and 12+ categories. The case study demonstrates how AI‑driven insights help global brands move faster, localize better, and compete more effectively in complex markets. The Challenge As Hisense expanded internationally, it faced rising complexity across global markets. Consumer preferences differed sharply across regions such as Western Europe, Eastern Europe, and Latin America, making a one‑size‑fits‑all approach ineffective. NIQ’s AI‑powered intelligence delivered the local market depth need
Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)6.5.2026 01:00:00 CEST | Press release
Phase 1 study has demonstrated pharmacokinetics (PK) equivalence between SB27 and KeytrudaPhase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 study on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), has met its primary pharmacokinetics (PK) endpoints. The randomized, double-blind, three-arm, parallel group, multicenter clinical trial demonstrated pharmacokinetic bioequivalence of SB27 (pembrolizumab) to the reference product Keytruda. Initiated in January 2024, Phase 1 study is being conducted in four countries, and is expected to be completed by November 2026.2 The study assessed pharmacokinetics, efficacy, safety, and immunogenicity of SB27, EU-sourced Keytruda, and US-sourced Keytruda in patients with stage II or IIIA non-small cell lung cancer (NSCLC) following complete resection and adjuvant platinum-based chemotherapy. 163 participants were randomized to receive SB27, EU-sourced Keytruda, or US-sour
Megaport Launches Built-In DDoS Protection Enabling On-Demand Network Resilience6.5.2026 00:00:00 CEST | Press release
Megaport DDoS Protection removes the trade-off between security, performance, and cost, offering rapid enterprise-grade mitigation. Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of Megaport DDoS Protection. This new, built-in security capability for Megaport Internet allows customers to filter malicious traffic directly within the Megaport network rather than routing it through a separate or external service, for mission-critical uptime without introducing additional latency or routing complexity. As enterprises increasingly migrate to distributed cloud environments, traditional DDoS mitigation has struggled to keep pace with cloud and distributed infrastructure adoption. Standard ISP solutions often resort to dropping all traffic and taking the service offline to protect the network, while external third-party providers force a "security detour" that reroutes traffic through public infrastructure, introducing s
IFF Reports First Quarter 2026 Results5.5.2026 22:23:00 CEST | Press release
Delivered solid top and bottom line Q1 resultsProgressing disciplined sale process for Food Ingredients businessReaffirms Full Year 2026 Financial Guidance IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Consolidated Summary: Management Commentary “IFF is off to a solid start in 2026, with first quarter results that reflect the customer focus and operational execution we’ve been building across the company,” said Erik Fyrwald, CEO of IFF. “We delivered volume growth in all four segments, improved profitability, and generated strong cash flow in the first quarter. As we look ahead, we are maintaining a disciplined approach to how we are planning the balance of the year as the current operating environment remains unsettled. We remained focused on advancing our commercial and innovation pipelines, driving productivity, and working with customers to offset inflation. This – when combined with our solid start to the year – derisks t
Logitech Announces Q4 and Full Fiscal Year 2026 Results5.5.2026 22:06:00 CEST | Press release
Strong FY 2026 Demonstrates Strategy and Operating Principles Are Delivering SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2026. For Fiscal Year 2026: Sales were $4.84 billion, up 6 percent in US dollars and 4 percent in constant currency compared to the prior year. GAAP operating income was $775 million, up 18 percent compared to the prior year. Non-GAAP operating income was $911 million, up 18 percent compared to the prior year. GAAP earnings per share was $4.80, up 16 percent compared to the prior year. Non-GAAP EPS was $5.78, up 19 percent compared to the prior year. Cash flow from operations was $1.04 billion. The year-ending cash balance was $1.7 billion. The Company returned $768 million of cash to shareholders through its annual dividend payment and share repurchases. For Q4 Fiscal Year 2026: Sales were $1.09 billion, up 7 percent in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
